Komori
Financial Results Presentation2160GNI Group Ltd.Pharmaceuticals

Financial Results Presentation for the Second Quarter of the Fiscal Year Ending December 2026

Following the completion of the acquisition of あゆみ製薬, the consolidated revenue forecast for the fiscal year ending December 2026 was raised from ¥27,158 million to ¥47,327 million to include the acquired company’s performance for the second half of the fiscal year. Meanwhile, profit attributable to owners of the parent was negative in the first half of fiscal 2026 due to acquisition-related expenses and upfront investments.

Worth reading
55In focus
0–100. This measures how worthwhile something is to read, not how good or bad the company is.
Direction
Mixed performance
Direction inferred from the company’s description.
Scale
20169
¥ million
Wording
Avoiding a definitive answer
How definitive the wording is.

Contents of this document

Financial Results PresentationSecond quarter of the fiscal year ending December 20267 items taken from the company’s own explanation
Financial Results Figures (The key points of this material are explained below)
Net Sales¥11,937 million-2.6%
Operating profit¥534 million
Ordinary income¥-87 million
Net income¥-588 million
Selling, general and administrative expenses¥11,420 million
Gross Profit Margin72.3%; year-on-year change: Not disclosed
Operating profit margin4.5%; year-on-year change: Not disclosed
Results for the three months of the current quarterPharmaceutical business revenue for the standalone second quarter of 2026 was ¥4,654 million, with an operating margin of 19.8%. Revenue increased 14.3% year on year. Standalone three-month figures for the consolidated group as a whole: Not disclosed
Full-year earnings forecast
Consolidated revenue
¥47,327 million
Pharmaceutical business revenue
¥40,622 million
Drug discovery business revenue
¥177 million
Medtech business revenue
¥5,647 million
Other businesses revenue
¥881 million
Gyre guidance
15,600～17,200
What the company explained in this material
Breakdown of Factors Affecting the ChangeReasons cited by the Company for the change in the figures.
  • Advisory fees associated with making あゆみ製薬 a wholly owned subsidiary¥738 million
  • Expenses related to Gyre’s acquisition of Cullgen as a subsidiary¥472 million
  • Share-based compensation expenses for Gyre and Gyre Pharmaceuticals¥966 million
  • Share-based compensation expenses for Cullgen¥144 million
  • Higher research and development expenses for the U.S. F351 IND application¥226 million
  • Gain from the reversal of accrued interest on Cullgen’s preferred shares¥6,596 million
  • BB impairment loss¥667 million
Assumptions Underlying the Business OutlookThe assumptions used by the company in preparing its forecast.
USD/JPY155
CNY/JPY21
New initiatives
  • Completion of the acquisition of all shares of あゆみ製薬ホールディングス
  • Completion of the integration of Gyre and Cullgen
  • Full consolidation of あゆみ製薬’s results from the third quarter
  • Promotion of group alliances by GNI Group’s Business Development Division
Key KPIsA metric the company considers important as a management benchmark.
  • Number of focus disease areas6 Field
  • Number of Employees1,400 people
  • Number of subsidiaries and equity-method affiliates30 companies
  • Number of pipeline and marketed products38 Engagements
  • Sales network of hospitals and pharmacies in Japan and China21,803+
Segment results
Pharmaceutical business
Revenue
¥8,202 million+14.4%
Operating profit
¥879 million-45.8%
Drug Discovery Business
Revenue
¥177 million-63.1%
Operating profit
¥7,183 million
MedTech Business
Revenue
¥2,928 million-26.6%
Operating profit
¥-1,837 million
Other businesses
Revenue
¥614 million+1.8%
Operating profit
¥-4,954 million
Market Size / Share
  • 125 million
    Market and patient numbersGlobal psoriasis patients
  • 18 million
    Market and patient numbersGlobal rheumatoid arthritis patients
  • Approximately 204,000
    Market and patient numbersU.S. lupus patients (2018)
Number of employees
Number of Employees1,400 people
Contents of this document
ItemDetails
Document typeFinancial Results Presentation
Fiscal Period CoveredSecond quarter of the fiscal year ending December 2026
Net Sales¥11,937 million (YoY -2.6%)
Operating profit¥534 million
Ordinary income¥-87 million
Net income¥-588 million
Gross Profit Margin72.3%; year-on-year change: Not disclosed
Operating profit margin4.5%; year-on-year change: Not disclosed
Selling, general and administrative expenses¥11,420 million
Results for the three months of the current quarterPharmaceutical business revenue for the standalone second quarter of 2026 was ¥4,654 million, with an operating margin of 19.8%. Revenue increased 14.3% year on year. Standalone three-month figures for the consolidated group as a whole: Not disclosed
Full-year earnings forecastConsolidated revenue ¥47,327 million / Pharmaceutical business revenue ¥40,622 million / Drug discovery business revenue ¥177 million / Medtech business revenue ¥5,647 million / Other businesses revenue ¥881 million / Gyre guidance 15,600～17,200
Segment resultsPharmaceutical business Revenue ¥8,202 million (YoY +14.4%) / Operating profit ¥879 million (YoY -45.8%) / Drug Discovery Business Revenue ¥177 million (YoY -63.1%) / Operating profit ¥7,183 million / MedTech Business Revenue ¥2,928 million (YoY -26.6%) / Operating profit ¥-1,837 million / Other businesses Revenue ¥614 million (YoY +1.8%) / Operating profit ¥-4,954 million
Breakdown of Factors Affecting the ChangeFactors Advisory fees associated with making あゆみ製薬 a wholly owned subsidiary / Amount ¥738 million, Factors Expenses related to Gyre’s acquisition of Cullgen as a subsidiary / Amount ¥472 million, Factors Share-based compensation expenses for Gyre and Gyre Pharmaceuticals / Amount ¥966 million, Factors Share-based compensation expenses for Cullgen / Amount ¥144 million, Factors Higher research and development expenses for the U.S. F351 IND application / Amount ¥226 million, Factors Gain from the reversal of accrued interest on Cullgen’s preferred shares / Amount ¥6,596 million, Factors BB impairment loss / Amount ¥667 million
Key KPIsIndicator name Number of focus disease areas / Value 6 Field / Year on year against the same period last year Not disclosed, Indicator name Number of Employees / Value 1,400 people / Year on year against the same period last year Not disclosed, Indicator name Number of subsidiaries and equity-method affiliates / Value 30 companies / Year on year against the same period last year Not disclosed, Indicator name Number of pipeline and marketed products / Value 38 Engagements / Year on year against the same period last year Not disclosed, Indicator name Sales network of hospitals and pharmacies in Japan and China / Value 21,803+ / Year on year against the same period last year Not disclosed
Number of employeesNumber of Employees 1,400 people / Change during the period Not disclosed / Hiring plan Not disclosed
Assumptions Underlying the Business OutlookUSD/JPY 155 / CNY/JPY 21
Market Size / ShareMarket and patient numbers Global psoriasis patients / Value 125 million, Market and patient numbers Global rheumatoid arthritis patients / Value 18 million, Market and patient numbers U.S. lupus patients (2018) / Value Approximately 204,000
New initiativesCompletion of the acquisition of all shares of あゆみ製薬ホールディングス, Completion of the integration of Gyre and Cullgen, Full consolidation of あゆみ製薬’s results from the third quarter, Promotion of group alliances by GNI Group’s Business Development Division
Items this document does not state (13)
Progress against full-year forecastSelf-assessment against the planUnit price and quantity metricsNumber of stores and locationsRisk amount incorporated into the outlookMedium-term management plan targetsFinancial targetsAnnual DividendPayout ratioAcquisition of treasury sharesCapital expendituresOrders received and order backlogKey points of the Q&A

These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.

The reasons the company gives

The company's own explanation, not something inferred from the numbers.

Following the completion of the acquisition of あゆみ製薬, the company’s performance will be consolidated from the third quarter onward, including the second half of the fiscal year. During the first half, acquisition costs, expenses related to Gyre’s acquisition of Cullgen as a subsidiary, share-based compensation expenses and higher research and development expenses were incurred. However, a ¥6,596 million gain from the reversal of accrued interest on Cullgen’s preferred shares contributed to an improvement in operating profit.

How to read this page

This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.
Financial Results Presentation for the Second Quarter of the Fiscal Year Ending December 2026 | GNI Group Ltd. (2160) timely disclosure | Komori